ARDX is expected to report earnings to fall 71.73% to -4 cents per share on August 06
Q2'26
Est.
$-0.04
Q1'26
Missed
by $0.02
Q4'25
Missed
by $0.02
Q3'25
Beat
by $0.06
Q2'25
Beat
by $0.05
The last earnings report on April 30 showed earnings per share of -15 cents, missing the estimate of -12 cents. With 1.80M shares outstanding, the current market capitalization sits at 1.22B.
A.I. Advisor
published General Information
General Information
a developer of therapeutic drugs that work in the gastrointestinal tract to treat cardio-renal, GI and metabolic diseases
A.I.dvisor indicates that over the last year, ARDX has been loosely correlated with VCYT. These tickers have moved in lockstep 45% of the time. This A.I.-generated data suggests there is some statistical probability that if ARDX jumps, then VCYT could also see price increases.
ARDX's RSI Oscillator ascends from oversold territory
The RSI Oscillator for ARDX moved out of oversold territory on July 01, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 28 similar instances when the indicator left oversold territory. In of the 28 cases the stock moved higher. This puts the odds of a move higher at .
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 9 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
The Moving Average Convergence Divergence (MACD) for ARDX just turned positive on July 23, 2026. Looking at past instances where ARDX's MACD turned positive, the stock continued to rise in of 45 cases over the following month. The odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where ARDX advanced for three days, in of 262 cases, the price rose further within the following month. The odds of a continued upward trend are .
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on July 16, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ARDX as a result. In of 82 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
ARDX moved below its 50-day moving average on June 25, 2026 date and that indicates a change from an upward trend to a downward trend.
The 50-day moving average for ARDX moved below the 200-day moving average on June 30, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ARDX declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. ARDX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (8.230) is normal, around the industry mean (19.620). P/E Ratio (0.000) is within average values for comparable stocks, (38.277). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (3.532). Dividend Yield (0.000) settles around the average of (0.020) among similar stocks. P/S Ratio (2.811) is also within normal values, averaging (420.906).
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ARDX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
